These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30852438)

  • 1. Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy.
    Gasparetto M; Pei S; Minhajuddin M; Stevens B; Smith CA; Seligman P
    Leuk Res; 2019 May; 80():1-10. PubMed ID: 30852438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells.
    Spinello I; Saulle E; Quaranta MT; Pasquini L; Pelosi E; Castelli G; Ottone T; Voso MT; Testa U; Labbaye C
    Haematologica; 2019 May; 104(5):973-985. PubMed ID: 30467201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
    Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
    Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
    Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
    Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MALAT1 knockdown inhibits proliferation and enhances cytarabine chemosensitivity by upregulating miR-96 in acute myeloid leukemia cells.
    Hu N; Chen L; Wang C; Zhao H
    Biomed Pharmacother; 2019 Apr; 112():108720. PubMed ID: 30970520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress.
    Chen Y; Zhang Z; Yang K; Du J; Xu Y; Liu S
    Oncogene; 2015 Jul; 34(29):3839-47. PubMed ID: 25284586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
    Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
    Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
    Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
    Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-20a regulates expression of the iron exporter ferroportin in lung cancer.
    Babu KR; Muckenthaler MU
    J Mol Med (Berl); 2016 Mar; 94(3):347-59. PubMed ID: 26560875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.
    Porter CC; Kim J; Fosmire S; Gearheart CM; van Linden A; Baturin D; Zaberezhnyy V; Patel PR; Gao D; Tan AC; DeGregori J
    Leukemia; 2012 Jun; 26(6):1266-76. PubMed ID: 22289989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
    Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
    Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepcidin Mediates Transcriptional Changes in Ferroportin mRNA in Differentiated Neuronal-Like PC12 Cells Subjected to Iron Challenge.
    Helgudottir SS; Lichota J; Burkhart A; Moos T
    Mol Neurobiol; 2019 Apr; 56(4):2362-2374. PubMed ID: 30027341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
    Chen L; Hu N; Wang C; Zhao H
    Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
    Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
    Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
    Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
    Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease.
    Zohn IE; De Domenico I; Pollock A; Ward DM; Goodman JF; Liang X; Sanchez AJ; Niswander L; Kaplan J
    Blood; 2007 May; 109(10):4174-80. PubMed ID: 17289807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia.
    Sun H; Ren Y; Zhou X; Chen Q; Liu Y; Zhu C; Ruan Y; Ruan H; Tong H; Ying S; Lin P
    Technol Cancer Res Treat; 2023; 22():15330338231207765. PubMed ID: 37872685
    [No Abstract]   [Full Text] [Related]  

  • 20. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.